BUSINESS

BMS’ Second CAR-T Therapy Abecma Approved in Japan

January 21, 2022

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

Bristol Myers Squibb on January 20 received Japanese regulatory approval for its second CAR-T cell therapy Abecma (idecabtagene vicleucel) for the treatment of relapsed or refractory multiple myeloma (MM).Abecma is now the first and only CAR-T therapy approved in Japan…

To read the full story

BMS’ CAR-T Therapy Abecma to Join NHI Price List on April 20
April 13, 2022
Drug Pricing Rules to Be Applied to BMS’ CAR-T Therapy Abecma: Chuikyo
January 27, 2022
BMS’ Second CAR-T Therapy Ide-Cel in Line for Approval in January
December 7, 2021

BUSINESS

DMD Gene Therapy Elevidys Hits Japan Market at Record Price
February 20, 2026
Bayer Eyes Kerendia as Standard Therapy for CKM Syndrome
February 20, 2026
Enhertu Accepted for EU Review in Post-Neoadjuvant HER2 Breast Cancer
February 20, 2026
SymBio Receives Grant for Antiviral Brincidofovir
February 20, 2026
Over 40% of Breast Surgeons Largely Unaware of Clinical Trials: Survey
February 20, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COLUMN

The Strategic MSL: Beyond Data Delivery, It’s About Impact

By Philip Carrigan

I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…

COMMENTARY

Hisamitsu’s MBO: Is Shareholder Accountability Trust-Building or a Shackle?

By Hayate Horiguchi

Following Hisamitsu Pharmaceutical’s decision to go private through a roughly 400 billion yen management buyout (MBO), industry observers are weighing…